Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases

Nanomedicine (Lond). 2016 May;11(10):1267-85. doi: 10.2217/nnm-2016-0019. Epub 2016 Apr 14.

Abstract

Alzheimer's disease and Parkinson's disease are the most common neurodegenerative diseases worldwide. Despite all the efforts made by the scientific community, current available treatments have limited effectiveness, without halting the progression of the disease. That is why, new molecules such as growth factors, antioxidants and metal chelators have been raised as new therapeutical approaches. However, these molecules have difficulties to cross the blood-brain barrier limiting its therapeutic effect. The development of nanometric drug delivery systems may permit a targeted and sustained release of old and new treatments offering a novel strategy to treat these neurodegenerative disorders. This review summarized the main investigated drug delivery systems as promising approaches to treat Alzheimer's disease and Parkinson's disease.

Keywords: Alzheimer’s disease; Parkinson’s disease; drug delivery systems; nanomedicine; nanotechnology.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / metabolism
  • Alzheimer Disease / physiopathology
  • Animals
  • Blood-Brain Barrier / drug effects
  • Blood-Brain Barrier / metabolism
  • Blood-Brain Barrier / physiopathology
  • Brain / drug effects
  • Brain / metabolism
  • Brain / physiopathology
  • Drug Carriers / chemistry
  • Drug Carriers / metabolism
  • Drug Delivery Systems / methods*
  • Drug Discovery
  • Humans
  • Nanomedicine / methods*
  • Nanoparticles / chemistry
  • Nanoparticles / metabolism
  • Neuroprotective Agents / administration & dosage
  • Neuroprotective Agents / pharmacokinetics
  • Neuroprotective Agents / therapeutic use
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / metabolism
  • Parkinson Disease / physiopathology

Substances

  • Drug Carriers
  • Neuroprotective Agents